Reference : Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis...
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/60002
Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
English
Kung, Annie Wai-Chee [ > > ]
Rachman, A Ichramsjah [ > > ]
Adam, MF John [ > > ]
Roeshadi, Djoko [ > > ]
Torralba, Tito [ > > ]
Navarra, Sandra [ > > ]
Gamilla, Zayda [ > > ]
Cañete, Arthur [ > > ]
de la Rosa, Miles [ > > ]
Tsai, KehSung [ > > ]
Lin, Hsiao-Yi [ > > ]
Soong, Yung Kuei [ > > ]
Lan, Joung-Liang [ > > ]
Hsu, Horng-Chaung [ > > ]
Tu, Shih-Te [ > > ]
Lin, Ruey-Mo [ > > ]
Yuktanandana, Pongsak [ > > ]
Songpatanasilp, Thawee [ > > ]
Ngarmukos, Srihatach [ > > ]
Soontrapa, Sugree [ > > ]
Soontrapa, Suppasin [ > > ]
Rojanasthien, Sattaya [ > > ]
Luevitoonvechkij, Sirichai [ > > ]
Leerapan, Taninnit [ > > ]
Albert, Adelin mailto [Université de Liège - ULg > Département des sciences de la santé publique > Informatique médicale et biostatistique - Département de mathématique >]
Vanbelle, Sophie mailto [Université de Liège - ULg > Département de mathématique > Département de mathématique >]
2009
International Journal of Rheumatic Diseases
12
216-224
Yes
International
[en] adherence ; bone marker ; compliance ; feedback ; ibandronate ; osteoporosis
[en] Aim: This study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker
feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis.
Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study
conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (£ 85 years old) who were
naı¨ve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at
3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and
adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate
treatment were also assessed.
Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients
were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels
were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their
osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients.
Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to
once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence,
but increased treatment satisfaction.
the BonAdAsia study group
http://hdl.handle.net/2268/60002
10.1111/j.1756-185X.2009.01413.x

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
bonadasia.pdfPublisher postprint180.33 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.